Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | parathyroid hormone 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K04588 secretin receptor, putative | Get druggable targets OG5_139196 | All targets in OG5_139196 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | kringle domain-containing protein | 0.012 | 0.0697 | 0.0697 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0594 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0594 | 1 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0594 | 1 | 1 |
Echinococcus granulosus | tissue type plasminogen activator | 0.012 | 0.0697 | 0.0697 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0594 | 1 | 1 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0594 | 1 | 1 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0594 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.0697 | 0.0697 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0594 | 1 | 1 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0594 | 1 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0594 | 1 | 1 |
Brugia malayi | Kringle domain containing protein | 0.012 | 0.0697 | 0.0697 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0362 | 0.5453 | 0.5453 |
Leishmania major | hypothetical protein, conserved | 0.012 | 0.0697 | 0.0697 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0594 | 1 | 0.5 |
Brugia malayi | Trypsin family protein | 0.0362 | 0.5453 | 0.5453 |
Onchocerca volvulus | 0.0362 | 0.5453 | 0.5112 | |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.012 | 0.0697 | 0.0697 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0594 | 1 | 1 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0594 | 1 | 1 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0594 | 1 | 0.5 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.012 | 0.0697 | 0.0697 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0594 | 1 | 1 |
Onchocerca volvulus | 0.0318 | 0.4585 | 0.418 | |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0594 | 1 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0594 | 1 | 1 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0594 | 1 | 1 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0594 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.012 | 0.0697 | 0.0697 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0594 | 1 | 1 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0594 | 1 | 1 |
Plasmodium vivax | RNA helicase-1, putative | 0.0594 | 1 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0362 | 0.5453 | 0.5453 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.012 | 0.0697 | 0.0697 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0594 | 1 | 1 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.012 | 0.0697 | 0.0697 |
Loa Loa (eye worm) | hypothetical protein | 0.0362 | 0.5453 | 0.5453 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0594 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.012 | 0.0697 | 0.0697 |
Brugia malayi | Protein kinase domain containing protein | 0.012 | 0.0697 | 0.0697 |
Loa Loa (eye worm) | hypothetical protein | 0.0362 | 0.5453 | 0.5453 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.6535 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.